Злокачественные опухоли у детей с нейрофиброматозом тип 1

Lloyd SK, Evans DG. Neurofibromatosis type 2 (NF2): diagnosis and management // Clin Neurol. 2013;115:957–967. https: // doi: 10.1016/B978-0-444-52902-2.00054-0

Ferner RE, Huson SM, Thomas N et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 // J Med Genet. 2007;44:(2):81–86. https: // doi: 10.1136/jmg.2006.045906

Stumpf DA, Alksne JF, Annegers JF et al. Neurofibromatosis conference statement. National Institutes of Health Consensus Development Conference // Arch Neurol. 1988;45:575–578.

Goldgar DE, Green P, Parry DM, Mulvihill JJ. Multipoint linkage analysis in neurofibromato sis type I: an international collaboration // Am J Hum Genet. 1989;44:6–12. PMID: 2491784.

Fain PR, Goldgar DE, Wallace MR et al. Refined physical and genetic mapping of the NF1 region on chromosome 17 // Am J Hum Genet. 1989;45:721–728. PubMed: 2573276.

Larribere L, Utika lJ. Multiple role of NF1 in the melanocyte lineage // Pigment Cell Melanoma Res. 2016;29:417–425. https: // doi: 10.1111/pcmr.12488

Xu GF, O’Connell P, Viskochil D et al. The neurofibromatosis type 1 gene encodes a protein related to GAP // Cell. 1990;62(3):599–608. https: // doi: 10.1016/0092-8674(90)90024-9.

Klose A, Ahmadian MR, Schuelke M et al. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1 // Hum Mol Genet. 1998;7(8):1261–8. https: // doi: 10.1093/hmg/7.8. 1261

Ballester R, Marchuk D, Boguski M et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins // Cell. 1990;63(4):851–859. https: // doi: 10.1016/0092-8674(90)90151-4

DeClue JE, Cohen BD, Lowy DR. Identification and characterization of the neurofibromatosis type 1 protein product // Proc Natl. Acad. Sci. USA. 1991;88:9914–9918–28. https: // doi: 10.1073/pnas.88.22.9914

Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP // Cell 2001;4(4):593–604. https: // doi: 10.1016/s0092-8674(01)00245-8

David H ,Viskochil DH, William T, Couldwell WT. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications // Neurosurg Focus. 2010;28(1):E8. https: // doi: 10.3171/2009.11

Tidyman W, Rauen K. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation // Curr Opin Genet Dev. 2009;19(3):230–236. https: // doi: 10.1016/ j.gde.2009. 04.001

Rauen KA, Huson SM, Burkitt-Wright E et al. Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues // Am J Med Genet A. 2015;167A(1):1–10. https: // doi: 10.1002/ajmg.a.36793.]

Kratz CP, Rapisuwon S, Reed H et al. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes // Am J Med Genet C Semin Med Genet. 2011;157C(2):83–89. https: // doi: 10.1002/ajmg.c.30300

Ratner N, Miller SJ.A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor // Nat Rev Cancer. 2015;15(5):290–301. https: // doi: 10.1038/nrc 391125

Tidyman WE, Rauen KA. Mutational and functional analysis in human Ras/MAP kinase genetic syndromes. // Methods Mol Biol. 2010;661:433–47. https: // doi: 10.1007/978-1-60761-795-2_2

John AM, Ruggieri M, Ferner R, Upadhyaya M. A search for evidence of somatic mutations in the NF1 gene // J Med Genet. 2000;37(1):44–9. https: // doi: 10.1136/jmg.37.1.44.

Weihong Xu, Xiao Yang, Xiaoxia Hu, Shibo Li. Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing // Int J Mol Med. 2014;34:53–60. https: // doi: 10.3892/ijmm.2014.1756

Koczkowska M, Chen Y, Callens T et al. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848 // Am J Hum Gen. 2017;102:1–19. https: // doi: 10.1016/j.ajhg.2017.12.001

Messiaen LM, Callens T, Mortier G et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects // Hum Mutat. 2000;15:541–555. https: // doi: 10.1002/1098-1004(200006)15:6<541

.Ars E, Serra E, García J et al. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1 // Hum Mol Genet. 2000;9:237–247. https: // doi: 10.1093/hmg/9.2.237

Serra E, Ars E, Ravella A et al. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations // Hum Genet. 2001;108:416–429. https: // doi: 10.1007/s004390100514

Zoller ME, Rembeck B, Oden A et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population // Cancer. 1997;79:2125–2131. PMID: 9179058.

Albers AC, Gutmann DH. Gliomas in patients with neurofibromatosis type 1 // Expert Rev Neurother. 2009;9:535–539. https: // doi: 10.1586/ern.09.4

Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates // Am J Hum Genet. 2001;68:1110–1118. https: // doi: 10.1086/320121

Pasmant E, Vidaud M, Vidaud D, Wolkenstein P. Neurofibromatosis type 1: from genotype to phenotype // J Med Genet. 2012;49:483–489. https: // doi: 10.1186/s13023-020-1310-3

Descheemaeker M, Roelandts K, De Raedt T et al. Intelligence in individuals with a neurofibromatosis type 1 microdeletion // Am J Med Genet. 2004;131:325–3263. https: // doi: 10.1002/ajmg.a.30346

Maertens O, Brems H, Vandesompele J et al. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas // Hum Mutat. 2006;7:030–1040. https: // doi: 10.1002/humu.20389

Jouhilahti EM, Peltonen S, Heape AM, Peltonen J. The pathoetiology of neurofibromatosis 1. // Am J Pathol. 2011;178(5):1932–39. https: // doi: 10.1016

Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations // Ann Neurol. 2007;61:189–198. https: // doi: 10.1097/ WNO. 0000000000000550

Evans D, Baser M, McGaughran J et al. Malignant peripheral nerves heath tumours in neurofibromatosis 1 // J Med Genet .2002;39:311–314. https: // doi: 10.1136 / jmg.39.5.311

Maertens O, Brems H, Vandesompele J T et al. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas // Hum Mutat. 2006;27:1030–1040. https: // doi: 10.1002/humu.20389

Serra E, Rosenbaum T, Winner U et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations // Hum Mol Genet. 2000;9:3055–3064. https: // doi: 10.1093/hmg/ 9.20.3055

Peltonen J, Peltonen S. Composition of neurofibromas, NF1 expression, and comparison of normal and NF1 haploinsufficient cells // In: Neurofibromatoses. Ed by D Kaufmann. Basel, Karger, 2008:129–142.

Smolle MA, Parry M, Jeys L, Abudu S, Grimer R. Synovial sarcoma: Do children do better? // Eur J Surg Oncol. 2019;45(2):254–260. https: // doi: 10.1016/j.ejso

De Raedt T, Maertens O, Serra E, Legius E: Somatic NF1 mutation s I tumors and other tissue // In: Neurofibromatoses. Edited by D Kaufmann. Basel, Karger, 2008:143–153

Side L.E, Emanuel P.D, Taylor B et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1 // Blood. 1998;2:267–272. PMID: 9639526

Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study // Br J Cancer. 2013;108:193–198. https: // doi: 10.1038/bjc.2012.535